Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / ARCH Venture Management, LLC
Form 13F · Q2 2026

ARCH Venture Management, LLC

CIK 1274403Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.1B
Reported book value
12
Positions
12
Quarters on record
Top 50
Positions

ARCH Venture Management, LLC — holdings

Top 12 positions of 12, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PBLS Parabilis Medicines Inc6.4M—$176M16.0%
2BEAM Beam Therapeutics Inc4.5M+0.0%$156M14.2%
3RAPP Rapport Therapeutics Inc3.7M+0.0%$155M14.1%
4SPTX Seaport Therapeutics Inc6.3M—$137M12.4%
5ERAS Erasca Inc7.1M+0.0%$130M11.8%
6VIR Vir Biotechnology Inc12.7M−1.7%$129M11.8%
7MAZE Maze Therapeutics Inc4.1M+0.0%$123M11.2%
8LYEL Lyell Immunopharma Inc3.2M+0.0%$46M4.1%
9GENB Generate Biomedicines Inc1.9M+0.0%$33M3.0%
10TXG 10X Genomics Inc217,834+0.0%$8M0.8%
11BOLD Boundless Bio Inc2.7M—$7M0.6%
12GOSS Gossamer Bio Inc8.1M+0.0%$1M0.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.